Aptorum Group Limited (APM)
APM Stock Price Chart
Explore Aptorum Group Limited interactive price chart. Choose custom timeframes to analyze APM price movements and trends.
APM Company Profile
Discover essential business fundamentals and corporate details for Aptorum Group Limited (APM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 Dec 2018
Employees
1.00
Website
https://www.aptorumgroup.comCEO
Chung Yuen Huen
Description
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
APM Financial Timeline
Browse a chronological timeline of Aptorum Group Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 28 Apr 2026
Earnings released on 30 Jul 2025
Earnings released on 28 Apr 2025
EPS came in at -$0.29 .
Earnings released on 20 Dec 2024
EPS came in at -$0.50 .
Earnings released on 30 Apr 2024
EPS came in at $0.51 surpassing the estimated -$2.70 by +119.04%.
Earnings released on 22 Dec 2023
EPS came in at -$1.43 surpassing the estimated -$2.60 by +45.19%, while revenue for the quarter reached $431.38K , missing expectations by -56.86%.
Earnings released on 28 Apr 2023
EPS came in at -$2.22 surpassing the estimated -$2.60 by +14.76%, while revenue for the quarter reached $768.43K , missing expectations by -3.95%.
Stock split effective on 23 Jan 2023
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Sept 2022
EPS came in at -$0.53 surpassing the estimated -$3.00 by +82.39%, while revenue for the quarter reached $527.46K , missing expectations by -34.07%.
Earnings released on 29 Apr 2022
EPS came in at -$2.52 surpassing the estimated -$3.30 by +23.76%, while revenue for the quarter reached $903.99K , beating expectations by +29.14%.
Earnings released on 3 Dec 2021
EPS came in at -$4.69 falling short of the estimated -$3.00 by -56.37%, while revenue for the quarter reached $637.78K , beating expectations by +6.30%.
Earnings released on 19 Apr 2021
EPS came in at $3.90 surpassing the estimated -$3.10 by +225.81%, while revenue for the quarter reached $584.24K , beating expectations by +46.06%.
APM Stock Performance
Access detailed APM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.